Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com

Raymond James reiterated an Outperform rating on BridgeBio Pharma with an $89 price target after Pfizer’s tafamidis settlements extended Vyndamax U.S. patent protection to June 1, 2031. The updated exclusivity timeline supports BridgeBio’s Attruby launch window, with analysts now seeing 7.5 to 8 years before generic competition. The company has also posted 126% revenue growth over the last twelve months and a 108% share price gain over the past year, reinforcing a constructive near-term outlook.

Analysis

The market is still underpricing the asymmetry in BBIO: the key second-order effect is not just a cleaner exclusivity runway, but a longer period for payer-contracting and formulary entrenchment before the generic overhang arrives. That matters because in rare-disease stabilization franchises, share gains tend to be sticky once patients are started, so the economic value of each additional quarter of clean runway compounds well beyond the expiry date itself.

The bigger signal is competitive. A delayed generic cliff lowers the probability that a second branded stabilizer entrant can win on price alone, which should keep the category more winner-take-most than investors may assume. If attrition stays low over the next 2-4 quarters, the market could start capitalizing Attruby more like a durable platform asset rather than a launch story, which would compress the discount rate on long-dated cash flows and support multiple expansion.

For PFE, this is a net positive only in the narrow sense that it monetizes litigation uncertainty without sacrificing much near-term value; strategically, it likely reduces future headline risk rather than changing the core earnings trajectory. The contrarian miss is that the current optimism may already be sufficient: if consensus had been discounting loss of exclusivity in the low 2030s, the revised date is helpful but not transformative, so upside from here depends more on execution than on the legal fix itself.

Catalyst timing is medium-term, not immediate. The next inflection points are quarterly Attruby demand prints, refill persistence, and any payer commentary on step edits or access; if those stay clean through the next 2-3 quarters, the stock can rerate on operating momentum, but any stumble would quickly unwind the legal-duration premium.

Key Decisions for Investors

• Long BBIO into the next 1-2 quarterly prints; use pullbacks as entry, targeting a 12-18 month horizon. Risk/reward favors upside if Attruby continues to take share and the market re-rates the franchise on durability.
• Buy BBIO call spreads 6-9 months out to express upside while capping premium burn; best if you expect a gradual rerating rather than an immediate squeeze.
• Avoid chasing PFE on this headline alone; treat it as a mild de-risking event rather than a catalyst for multiple expansion. If already long, consider trimming into strength if the move reflects legal relief more than operating improvement.
• Pair trade: long BBIO / short a basket of large-cap pharma with patent-expiry overhangs over a 3-6 month window. The setup favors names with improving launch economics and clean legal visibility versus legacy cash cows with slower growth.
• Set a tactical stop on BBIO if payer data or prescription growth decelerates over the next two reporting cycles; the thesis depends on commercial traction, not just the patent settlement.